Direct%252525252525252525252525252525252525252520oral%252525252525252525252525252525252525252520anticoagulants

# Direct Oral Anticoagulants (DOACs) ## Overview DOACs are a class of oral medications that directly inhibit specific factors in the blood coagulation cascade. This group includes direct thrombin inhibitors (e.g., dabigatran) and direct Factor Xa inhibitors (e.g., apixaban, edoxaban, rivaroxaban). ## Primary Indications * **Non-valvular atrial fibrillation (NVAF):** Prevention of stroke and systemic embolism. * **Deep vein thrombosis (DVT) and pulmonary embolism (PE):** Treatment and prevention of recurrence. * **Prophylaxis of VTE:** In certain orthopedic surgery patients (hip or knee replacement). ## Adult Dosing * **Apixaban:** * NVAF: 5 mg twice daily. * DVT/PE Treatment/Recurrence: 10 mg twice daily for 7 days, then 5 mg twice daily. * VTE Prophylaxis (orthopedic surgery): 2.5 mg twice daily, initiated 12-24 hours post-surgery. * **Dabigatran:** * NVAF: 150 mg twice daily. A 110 mg twice daily dose may be used in specific populations (e.g., age >80 or moderate CrCl). * DVT/PE Treatment/Prophylaxis: 150 mg twice daily, typically after initial parenteral anticoagulation for 5 days. * **Edoxaban:** * NVAF: 60 mg once daily. * DVT/PE Treatment/Recurrence: 60 mg once daily, typically after initial parenteral anticoagulation for 5 days. * **Rivaroxaban:** * NVAF: 20 mg once daily. * DVT/PE Treatment/Recurrence: 15 mg once daily for 21 days, then 20 mg once daily. * VTE Prophylaxis (orthopedic surgery): 10 mg once daily, initiated 6-12 hours post-surgery. ## Pediatric Dosing Pediatric dosing for DOACs is generally not well-established for all indications. Specific agents and limited indications may have available pediatric dosing based on age and weight, often requiring specialized guidelines or protocols. For example, rivaroxaban and dabigatran have some pediatric indications and dosing recommendations that vary significantly by age group and weight. Consult pediatric-specific guidelines. ## Dose Adjustments * **Renal Impairment:** Dosing adjustments are often required based on creatinine clearance (CrCl). * **Apixaban:** Reduce to 2.5 mg twice daily if patient has ≥2 of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. * **Dabigatran:** Reduce dose in moderate renal impairment (CrCl 30-50 mL/min) and avoid in severe impairment (CrCl <30 mL/min). * **Edoxaban:** Avoid in CrCl <15 mL/min. Reduce dose in patients with CrCl 15-50 mL/min. * **Rivaroxaban:** Reduce dose in moderate renal impairment (CrCl 30-50 mL/min) and avoid in severe impairment (CrCl <30 mL/min). * **Hepatic Impairment:** Generally avoid in severe hepatic impairment or liver disease associated with coagulopathy. * **Drug Interactions:** Dose adjustments may be necessary when co-administered with P-glycoprotein (P-gp) or strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers. ## Contraindications * Active pathological bleeding. * Known history of hypersensitivity to the drug or its excipients. * Severe hepatic impairment or liver disease. * Conditions that significantly increase bleeding risk. ## Adverse Effects The most significant adverse effect is **bleeding**. Other common effects may include: * Gastrointestinal upset (dyspepsia, nausea) * Bruising ## Key Drug Interactions * **Strong CYP3A4 and P-gp inhibitors (e.g., ketoconazole, ritonavir):** May increase DOAC concentrations and bleeding risk. Avoid or use with caution. * **Strong CYP3A4 and P-gp inducers (e.g., rifampin, carbamazepine):** May decrease DOAC concentrations and efficacy. Avoid or use with caution. * **Other anticoagulants and antiplatelets (e.g., warfarin, aspirin, NSAIDs):** Increased risk of bleeding. Concomitant use requires careful consideration of risk versus benefit and may necessitate dose adjustments or specific monitoring. * **P-gp substrates (e.g., digoxin):** Some DOACs can affect digoxin levels. ## Monitoring * Routine monitoring of coagulation parameters (like INR) is generally **not** required or recommended for most DOACs. * Clinical assessment for signs and symptoms of bleeding or thrombosis is crucial. * Renal function should be assessed periodically, especially in patients with risk factors for renal decline. * For patients requiring reversal of anticoagulation, specific reversal agents exist for each DOAC, but emergent management is complex. ## Clinical Pearls * DOACs offer a more predictable anticoagulant response compared to warfarin, often eliminating the need for routine INR monitoring. * Timing of doses is important for consistent anticoagulation; patients should be advised to take doses at the same time(s) each day. * If a dose is missed, patients should take it as soon as they remember unless it is almost time for the next dose. They should then resume the regular schedule. Patients should not double doses. * Discontinuation of DOACs, especially in NVAF, significantly increases the risk of stroke. Restarting anticoagulation should be carefully managed. * Consider patient adherence, renal function, liver function, drug interactions, and bleeding risk before initiating therapy. * Specific reversal agents (e.g., idarucizumab for dabigatran; andexanet alfa for apixaban and rivaroxaban) are available for life-threatening bleeding, but their use is guided by specific criteria and institutional protocols. *** *Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and institutional guidelines for definitive dosing, safety, and management guidance.*